术尔泰在输卵管通液治疗中的临床疗效观察

目的:观察术尔泰用于输卵管通液治疗的疗效。方法:对2009年3月至2011年3月在我院妇产科门诊经子宫输卵管造影诊断,对其中805例输卵管通而不畅的患者,进行随机分组,对照组400例,观察组405例,分别给予两种方法治疗,对照组给予а糜蛋白酶4000u+庆大霉素8万单位+地塞米松5mg+2%利多卡因2 ml+生理盐水20 ml行输卵管通液治疗,观察组给予术尔泰30 ml行输卵管通液治疗,两组均隔日治疗一次,四次治疗为一个疗程。详细观察记录治疗效果,比较两组患者的输卵管通畅情况,并分别在1月、3月、6月、12月进行随访,比较受孕情况。结果:治疗一疗程后,观察组405例中,输卵管通畅247例,仍然通而不畅有158例,输卵管通畅率为61%,随访1年后受孕73例,受孕率为29.6%;对照组400例中,输卵管通畅80例,仍然通而不畅的有320例,输卵管通畅率为20%,随访1年后受孕4例,受孕率为5%,两组在通畅率和受孕率方面比较,观察组明显优于对照组,均有统计学意义(P0.05)。结论:用术尔泰在门诊行子宫输卵管通液治疗,简便、经济、无创、病人痛苦少等优点,输卵管通畅率及术后受孕率均较高,适合输卵管阻塞性不孕患者的首选治疗方法。

The Clinical Curative Effect of Shuertai in Therapy of Hydrotubation

Objective： To observe the effect of shuertai for hydrotubation therapy. Methods： We rolled 805 patients, who were di- agnosed tubal pass while poor by hysterosalpingography, from March 2009 to March 2011 in the obstetrics and gynecology clinic in the First Affiliated Hospital of Chongqing Medical University, then we divided them into 2 groups randomly, 400 patients in the con- trol group and 405 patients in the observation group. We used the combined drugs in the control group, chymotrypsin 4000 u, gentami- cin 80000 u, dexamethasone 5 mg, 2% lidocaine 2 ml, and NaC1 20 ml, while we used 30 ml shuertai in the observation group for hy- drotubation treatment, both in alternate days and total four times as a period of treatment. All patients were followed up in one month, 3 months, 6 months and 12 months after hydrotubation therapy. Detailed treatment effects were recorded, to compare the effects of these two different treatments. Results： After a period of treatment, in the observation group there were 247 cases of tubal patency, 158 cases of still pass while poor, tubal patency rate was 61%, 73 cases of the patients got pregnancy, pregnancy rate was 29.6%. While in the control group there were only 80 cases of tubal patency, 320 cases of still pass while poor, tubal patency rate was 20%, after 1 year follow-up only 4 patients got pregnancy, conception rate was 5%. So there are statistical significance （P 〈 0.05） between the two groups both in the tubal patency rate and pregnancy rate. Conclusions： Shuertai may be a prefferred choice for the infertile women with tubal obstruction because it is more effective in tubalpatency rate and pregnancy rate for hydrotubation therapy, and also simple, economi noninvasive, less painful.